Daunorubicin liposomal Pregnancy and Breastfeeding Warnings

Brand names: DaunoXome

Daunorubicin liposomal Pregnancy Warnings

Use is contraindicated.

Comments:
-This drug may induce chromosomal damage in human spermatozoa.
-Men should receive counseling on sperm cryopreservation before the start of therapy due to the possibility of irreversible infertility.
-Men should use effective contraceptive methods during and for 6 months after therapy.
-Women of childbearing potential should use effective contraceptive methods if they or their male partners are taking this drug during and for 6 months after therapy.
-Genetic counseling is recommended for women who want to become pregnant after completing therapy with this drug.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Cardiologic examination and a blood count are recommended in fetuses and newborns born to mothers who received this drug during pregnancy.

Animal studies have revealed evidence of embryotoxicity, teratogenicity, mutagenicity, and carcinogenicity. There are no controlled data in human pregnancy, although a few women who received this drug during the second and third trimesters of pregnancy have delivered apparently normal infants.

See references

Daunorubicin liposomal Breastfeeding Warnings

Use is contraindicated.

Excreted into human milk: Unknown; however, other anthracyclines are excreted in breast milk.
Excreted into animal milk: Data not available

Comments:
-The effects in the nursing infant are unknown.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer